F7 and hemophilia A: However, inhibitor development is the most common and most serious complication in hemophilia A patients and it occurs in up to 30% of patients with severe hemophilia A.[8] The current standard hemostatic agents for patients with inhibitor are recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrate (APCC).